Trailing-twelve-month (TTM) revenue is $21.05 Billion with a year-over-year growth of +5.24%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $5,131,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-31 | $5,230,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-23 |
| Q1 FY2026Period ended 2026-03-31 | $5,324,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $5,361,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $21,046,000,000 |
Current P/S: $70,336,613,100 market capitalization ÷ $21,046,000,000 TTM revenue = 3.34x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T20:00:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $5.36B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T20:00:03.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Oral, Personal and Home Care | $13.6B | $14.1B | $14.3B | $15.2B | $15.6B | $15.8B |
| Pet Nutrition | $2.9B | $3.3B | $3.7B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Oral, Personal and Home Care | $4.8B |
| Pet Nutrition | $3.1B |
$21.05B
$21.05 Billion
+5.24%
vs. $20.00B a year ago (TTM)
+4.26%
5 Year compound annual growth rate
1 Year
+5.24%
3 Year
+4.06%
5 Year
+4.26%
10 Year
+3.10%
15 Year
+1.80%
20 Year
+2.98%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $20.38B | +$281.00M | +1.40% |
| 2024 | $20.10B | +$644.00M | +3.31% |
| 2023 | $19.46B | +$1.49B | +8.29% |
| 2022 | $17.97B | +$546.00M | +3.13% |
| 2021 | $17.42B | +$950.00M | +5.77% |
| 2020 |
TTM Growth
+5.24%
3-Year CAGR
+4.06%
5-Year CAGR
+4.26%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T20:00:03.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $4.5B |
| $4.6B |
| $16.47B |
| +$778.00M |
| +4.96% |
| 2019 | $15.69B | +$149.00M | +0.96% |
| 2018 | $15.54B | +$90.00M | +0.58% |
| 2017 | $15.45B | +$259.00M | +1.70% |
| 2016 | $15.20B | ($839.00M) | (5.23%) |
